KUALA LUMPUR, Sept 5 (Bernama) -- Yourgene Health plc (Yourgene), an international molecular diagnostics group, has launched the Yourgene MagBench Automated DNA Extraction Instrument and Kit, which is available to Sage customers across Asia Pacific (APAC) and the Middle East.
MagBench solution offers a simple, fast and cost-efficient, bench-top robotic cell-free DNA (cfDNA) extraction workstation optimised for Yourgene’s Sage 32 NIPT Workflow, according to a statement.
This provides clinical laboratories with a streamlined end-to-end solution, from sample to report, enabling them to provide a more accurate and competitive non-invasive prenatal testing (NIPT) service.
Yourgene Vice President of Sales, APAC, Dr Rob Henke said the company is committed to delivering best-in-class NIPT solutions, where precision and quality assurance are key.
“MagBench enables an economical and automated NIPT workflow. Reducing manual procedures improves user experience, facilitating true walkaway time while minimising the risk of contamination and improving testing accuracy.
“This decreases the number of screening failures, greatly improves efficiency and helps lower expectant parents’ anxiety,” he said.
The instrument is easy to use, quick to install and provides users with an intuitive touchscreen user interface with built-in protocols, offering fast run times and flexible sample throughput to meet the laboratory’s testing needs.
Meanwhile, the kit comprises sample and elution tubes, pre-sealed cartridges with all the reagents needed for efficient cfDNA purification, and individually packaged tip sets with a unique cross-notch design for precise volume pipetting.
Increased automation during DNA extraction, limits hands-on procedures, minimising the chance of human error, and with single-use tip disposal and a built-in UV lamp for decontamination between runs, it minimises the risk of cross contamination. It also improves the accuracy and consistency of pipetting, resulting in a lower failure rate.
The NIPT workflow includes extracting DNA from the maternal plasma using MagBench, followed by library preparation and enrichment, sequencing, and Sage Link analysis to estimate the risk of a foetus having trisomy 21, 18 or 13, rare autosomal aneuploidies, sex chromosome aneuploidies and the most clinically relevant microdeletions.
-- BERNAMA
No comments:
Post a Comment